DICK’S Sporting Goods (DKS) has quietly developed an interesting insider-buying setup following its sharp post-earnings selloff.
Market Analysis
Surging Yields Create Risk — And Opportunity
With 10-year treasury yields now at two-decade highs, the topic of rates has dominated markets. Rising rates adds meaningful stress to the economy at large — creating both risk and opportunity for traders. The market’s most rate-sensitive corners have taken the brunt of the damage. Small caps (IWM), utilities (XLU), homebuilders (ITB), and industrials (XLI) […]
Index Put Protection Is Cheap With 10-Year Treasury Bonds at 5.3%
SpotGamma founder Brent Kochuba joined tastylive to explain why index put protection stays cheap with the 10-year at 5.3% and bond volatility climbing.
Friday Jobs Report Preview: What the Market Wants to See
The stock market faces its biggest economic test of the week Friday morning when the September jobs report is released at 8:30 a.m. ET.
Micron Earnings Preview: Can the AI Memory Boom Keep Delivering?
Micron (MU) reports earnings Wednesday after the close, and this may be one of the most important semiconductor reports of the week.
Index Put Demand Returns Ahead of Friday’s Jobs Report
Brent Kochuba, founder of SpotGamma, on tastylive: index put demand, same-day options flow, and why weekly vol prices almost no risk premium.
AI Trade Drives Nasdaq, Small Caps Lag Behind
Brent Kochuba, founder of SpotGamma, joined CNBC on September 29 to discuss the AI trade market breadth split and why Micron is the next test.
META Rewrites the AI Trade
Meta’s new Muse AI Agent has done what a year of capex headlines could not: it has convinced the market that the company’s $200 billion investment in AI has a consumer-facing payoff. META rallied 13% over the past week and pushed toward 52-week highs as the personal agent app topped the download charts. The enthusiasm […]
Salesforce: A $1 Million Insider Buy Near a Key Options Level
Salesforce director David Kirk bought about $1 million of CRM stock. A look at the fundamentals, key chart levels and SpotGamma options positioning.
Erasca’s November Catalyst: Promising Data, High Expectations and Strategic Optionality
The company’s lead drug, ERAS-0015, has shown encouraging early results. On November 20, Erasca will provide updated clinical data that could produce a large move in the stock.